CH532082A - Magnesium ortate-glycinates - Google Patents
Magnesium ortate-glycinatesInfo
- Publication number
- CH532082A CH532082A CH1120872A CH1120872A CH532082A CH 532082 A CH532082 A CH 532082A CH 1120872 A CH1120872 A CH 1120872A CH 1120872 A CH1120872 A CH 1120872A CH 532082 A CH532082 A CH 532082A
- Authority
- CH
- Switzerland
- Prior art keywords
- magnesium
- glycinate
- orotate
- complex
- ortate
- Prior art date
Links
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims description 4
- 229910052749 magnesium Inorganic materials 0.000 title claims description 4
- 239000011777 magnesium Substances 0.000 title claims description 4
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims abstract description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004471 Glycine Substances 0.000 claims abstract description 5
- 229960005010 orotic acid Drugs 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims abstract 2
- HSYYCUNXLJEMBC-UHFFFAOYSA-L magnesium;2-aminoacetate;2,4-dioxo-1h-pyrimidine-6-carboxylate Chemical compound [Mg+2].NCC([O-])=O.[O-]C(=O)C1=CC(=O)NC(=O)N1 HSYYCUNXLJEMBC-UHFFFAOYSA-L 0.000 claims description 8
- 229940091250 magnesium supplement Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229940004916 magnesium glycinate Drugs 0.000 claims description 2
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 description 4
- 229960000407 magnesium orotate Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The double salt orotate-Mg-glycinate of formula: and the complex salt (orotate-Mg-glycinate)2.Mg (glycinate)2 useful for treatment of Mg deficiencies are prepd. adding Mg to a soln. or suspension of orotic acid and glycine in water.
Description
Verfahren zum Herstellen eines Komplexes von Magnesiumorotatglycinat Die Erfindung bezieht sich auf ein Verfahren zum Herstellen eines Komplexes von Magnesiumorotatgly- cinat der Formel
EMI0001.0002
das heisst
EMI0001.0003
Das Magnesium-Orotat-Glycinat wird zur Intensiv therapie bei Magnesium-Mangelkrankheiten eingesetzt. Ein besonderer Vorzug gegenüber anderen Magnesium- Salzen ist die Tatsache, dass diese Verbindung im Blut nicht dissoziiert und der Orotsäureanteil das Magne sium-Ion mit einer gewissen Zwangsläufigkeit in die Zellen einschleppt.
Von Vorteil gegenüber= den klassi schen Magnesium-Salzen ist auch, dass bei dem Mägne- siumorotatglycinat der Erfindung der Anion-Anteil gleichzeitig therapeutischen Effekt hat. So wird der Orotsäure-Anteil direkt in die Nukleinsäuren, also in die Kerneiweisse, eingebaut.
Wesentlich ist auch die bemerkenswerte Ungiftigkeit dieser Verbindung. Die toxische no-effect-Grenze liegt bei einer Dosis von ca. 2500 mg !kg Körpergewicht Tier.
.Der neue Komplex ist - wie Gefunden wurde - in Wasser weit löslicher als die bisher bekannten und verwendeten Orotatsalze, z. B. das Magnesiumorotat.
Die beigefügte Tabelle zeigt diese Löslichkeiten im Vergleich zu Magnesiumorotat.
Die Löslichkeit von Magnesiumorotat ist äusserst gering; bei Raumtemperatur lösen sich etwa nur 0,4 Magnesiumorotat und weniger in Wasser, selbst bei der Zugabe von Glycin.
Die Löslichkeit des Komplexes Magnesiumorotatgly- cinat Magnesiumglycinat ist höher und beträgt " 9-10%. Die Herstellung des Magnesiumorotatglycinat-Kom- plexes gelingt ohne weiteres durch Eingeben von Oro- säure einerseits und Glycin andererseits in Wasser, zum Beispiel von einer Temperatur von 80 C, unter Rühren und portionsweises Zusetzen von Magnesium.
Die Temperatur, zum Beispiel von 80 -C, wird zweckmässig während etwa 6 Stunden aufrechterhalten. Die Lösung wird dann zweckmässig filtriert und je nach Bedarf mit einer organischen oder anorganischen Säure auf einen gewünschten pH-Wert eingestellt.
Zur Herstellung des Komplexes aus Magnesium- orotatglycinat und Magnesiumglycinat werden zweck- mässig in 4000 ml Wasser bei 80 -C 356g Orotsäure und 300 a Glycin unter Rühren zugegeben und danach 72 a Magnesium in kleinen Portionen von etwa 5 g zugesetzt, wobei eine Gasentwicklung eintritt.
EMI0003.0000
Process for preparing a complex of magnesium orotate glycinate The invention relates to a process for preparing a complex of magnesium orotate glycinate of the formula
EMI0001.0002
this means
EMI0001.0003
Magnesium orotate glycinate is used for intensive therapy for magnesium deficiency diseases. A particular advantage compared to other magnesium salts is the fact that this compound does not dissociate in the blood and the orotic acid component brings the magnesium ion into the cells with a certain degree of inevitability.
Another advantage over the classic magnesium salts is that in the magnesium orotate glycinate of the invention the anion component also has a therapeutic effect. The orotic acid component is incorporated directly into the nucleic acids, i.e. into the nuclear proteins.
The remarkable non-toxicity of this compound is also essential. The toxic no-effect limit is a dose of approx. 2500 mg! Kg of animal body weight.
The new complex is - as was found - far more soluble in water than the previously known and used orotate salts, e.g. B. the magnesium orotate.
The attached table shows these solubilities compared to magnesium orotate.
The solubility of magnesium orotate is extremely low; at room temperature only about 0.4 magnesium orotate and less dissolve in water, even with the addition of glycine.
The solubility of the magnesium orotate glycinate complex is higher and is 9-10%. The magnesium orotate glycinate complex can be produced easily by adding oroic acid on the one hand and glycine on the other to water, for example at a temperature of 80 ° C , while stirring and adding magnesium in portions.
The temperature, for example 80 ° C, is expediently maintained for about 6 hours. The solution is then conveniently filtered and adjusted to a desired pH value with an organic or inorganic acid, as required.
To prepare the complex of magnesium orotate glycinate and magnesium glycinate, it is advisable to add 4000 ml of water at 80 to 356 g of orotic acid and 300 μg of glycine with stirring and then add 72 μg of magnesium in small portions of about 5 g, gas being generated.
EMI0003.0000
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19691924174 DE1924174C3 (en) | 1969-05-12 | Magnesium Orotate Glycinate | |
| CH369670A CH532081A (en) | 1969-05-12 | 1970-03-12 | Process for the production of magnesium orotate glycinate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH532082A true CH532082A (en) | 1972-12-31 |
Family
ID=25693645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1120872A CH532082A (en) | 1969-05-12 | 1970-03-12 | Magnesium ortate-glycinates |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH532082A (en) |
-
1970
- 1970-03-12 CH CH1120872A patent/CH532082A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1445154C3 (en) | 1,4-Dihydro-1,8-naphthyridinderi derivatives and a process for their preparation | |
| CH532082A (en) | Magnesium ortate-glycinates | |
| DE1924174A1 (en) | Magnesium Orotate Glycinate | |
| DE900097C (en) | Process for the production of hexamethylene-1,6-bis-trimethylammonium bitartrate | |
| DE2327193C3 (en) | N- (Diethylaminoethyl) -2-methoxy-5methylsulfonylbenzamide, its salts, processes for the preparation of these compounds and medicaments containing these compounds | |
| AT214457B (en) | Process for the production of complex protein compounds of the metal complexes of the chlorophyll and porphyrin series and their breakdown products | |
| DE938249C (en) | Process for the preparation of dihydrocodeine hydrorhodanide | |
| DE951161C (en) | Process for the production of complex fibrin compounds of the metal complexes of the chlorophyll and porphyrin series | |
| AT203501B (en) | Process for the preparation of new derivatives of piperazine | |
| DE1593838C3 (en) | Rutin tri- (dihydroxypropyl) ether and process for its preparation | |
| AT119962B (en) | Process for the preparation of N-chloroiodine compounds of α-aminopyridine and its derivatives. | |
| DE830646C (en) | Process for the preparation of an N, N-dimethyl-N '- (2-pyridyl) -N' - (halo-2-thienylmethyl) -aethylene diamine | |
| DE817754C (en) | Process for the isolation of piperazine from reaction mixtures containing it | |
| DE870277C (en) | Process for the preparation of salts of p-amino-salicylic acid | |
| AT324556B (en) | METHOD FOR PRODUCING CEPHALEXINE MONOHYDRATE | |
| DE905371C (en) | Process for the preparation of new therapeutically effective quaternary ammonium salts | |
| AT100211B (en) | Process for the preparation of new organic arsenic compounds. | |
| DE731912C (en) | Process for the production of pellets of sulfanilamide | |
| DE1203781B (en) | Process for the preparation of trypanocidally active phenanthridinium derivatives | |
| AT284147B (en) | Process for the preparation of the new compound 8 {2- [N- (α-methylphenethyl) methylamine] ethylamine} caffeine | |
| AT256125B (en) | Process for the production of new metal complexes | |
| AT220288B (en) | Process for the preparation of new therapeutically effective esters of erythromycin | |
| AT203000B (en) | Process for the preparation of new salts of 4,6-dioxyisophthalic acid and 5-halogen (especially 5-iodine) - 4,6-dioxyisophthalic acid | |
| DE948158C (en) | Process for the preparation of zinc complex salts of tripeptides | |
| DE644078C (en) | Process for the preparation of a salt of 4-oxy-3-acetylaminophenyl-1-arsic acid with the toxin of iso-octylhydrocupreine (vuzinotoxin) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |